title: [Estrogen-progestin contraception. Advantages of estrogen reduction].
abstract: Among the low dose oral contraceptives that is to say less than 50 mcg of ethinylestradiol per pill one must single out the pills made of a third generation progestagen (desogestrel, gestodene, norgestimate) from the others. The contraceptive efficacy (tested on the Pearl index) according to the files of government authorities visa (AMM) is equivalent for all the oral contraceptives whatever their composition (between 0 to 0.07 women year). The clinical tolerance of the low dose pills of the 3rd generation is comparable to that of the other low dose pills. Is there any advantage then in prescribing them? The most important advantage is the decrease of metabolic and vascular effects. The use of so-called third generation progestive, besides the beneficial effects an lipidic and glucidic metabolisms, has mainly enabled the decrease of the estrogen doses of progestagens. The ethinylestradiol is directly implicated in the risk of venous thrombosis: hemostasis the modifications are less important with 30 mcg than with 50, 20 than 30 mcg. Relying on theoretical arguments one could have estimated that minipills would lead to an insufficient ovarian slow down. These hypothesis are contradicted by recent studies from Falsetti and Benagiano who studied the rates of FSH and LH under minipills. This does not include the variability and the individual sensitiveness of the patients and as well the reason following which minipills would favor functional ovarian cysts, lies on the confusion made between a cyst and a 20 mm diameter follicule.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Hôpital Jean-Rostand, Sevres.
authors.forename: J
authors.initials: J
authors.lastname: Cohen
mesh_terms: D001943:Breast Neoplasms / Q000139:chemically induced / Q000453:epidemiology; D002986:Clinical Trials as Topic; D003277:Contraceptives, Oral, Combined / Q000145:classification / Q000494:pharmacology / Q000627:therapeutic use*; D004997:Ethinyl Estradiol / Q000145:classification / Q000494:pharmacology / Q000600:supply & distribution / Q000627:therapeutic use*; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D005947:Glucose / Q000378:metabolism; D006801:Humans; D050356:Lipid Metabolism; D007986:Luteinizing Hormone / Q000097:blood / Q000187:drug effects; D010048:Ovarian Cysts / Q000139:chemically induced / Q000453:epidemiology; D011372:Progestins / Q000145:classification / Q000494:pharmacology / Q000600:supply & distribution / Q000627:therapeutic use*; D012307:Risk Factors; D013924:Thrombophlebitis / Q000139:chemically induced / Q000453:epidemiology
chemical_list: D003277:Contraceptives, Oral, Combined; D011372:Progestins; D004997:Ethinyl Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D005947:Glucose
vernacular_title: La contraception estroprogestative. Avantages de la diminution des estrogènes.